DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 211 filers reported holding DENALI THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 4.43 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $3,529,000 | +322.1% | 115,000 | +342.3% | 0.69% | +214.7% |
| Q1 2022 | $836,000 | -81.3% | 26,000 | -74.0% | 0.22% | -82.3% |
| Q4 2021 | $4,460,000 | +17.9% | 100,000 | +33.3% | 1.23% | +13.4% |
| Q3 2021 | $3,784,000 | -40.4% | 75,000 | -7.4% | 1.09% | -37.8% |
| Q2 2021 | $6,354,000 | +14.7% | 81,000 | -16.5% | 1.75% | +10.5% |
| Q1 2021 | $5,539,000 | +15.0% | 97,000 | +68.7% | 1.58% | +10.5% |
| Q4 2020 | $4,816,000 | -18.5% | 57,500 | -65.2% | 1.43% | -20.8% |
| Q3 2020 | $5,912,000 | +88.1% | 165,000 | +26.9% | 1.81% | +92.1% |
| Q2 2020 | $3,143,000 | +99.4% | 130,000 | +44.4% | 0.94% | +35.6% |
| Q1 2020 | $1,576,000 | – | 90,000 | – | 0.69% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 7,460,732 | $240,012,000 | 28.78% |
| Casdin Capital, LLC | 1,500,000 | $48,255,000 | 2.16% |
| Flagship Pioneering Inc. | 2,619,968 | $84,284,000 | 1.98% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 38,000 | $8,192,000 | 1.85% |
| Yiheng Capital Management, L.P. | 1,014,684 | $32,642,000 | 1.49% |
| SECTORAL ASSET MANAGEMENT INC | 207,100 | $6,662,000 | 1.18% |
| Artal Group S.A. | 600,000 | $19,302,000 | 0.81% |
| GILDER GAGNON HOWE & CO LLC | 2,619,217 | $84,260,000 | 0.78% |
| Temasek Holdings (Private) Ltd | 5,369,487 | $172,736,397 | 0.73% |
| BRANDYWINE MANAGERS, LLC | 9,601 | $309,000 | 0.53% |